Consumer Access To New Biomedical Advances Dependent On System Reengineering: Benefit Plan Design And Delivery System Structure

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst

Industry Analysis

Since 1990, there has been an 'explosion' of new pharmaceutical agents available to individuals suffering from mental illnesses. But, consumer access to these new medications has been limited. At professional meetings, there is great discussion about how benefit plan management issues affect consumer access to medications. Restructuring the process for and assumptions used to design pharmacy benefit plans and plan performance measurements are key to improve access to these new technologies.

That said, there is another reason . . .